JP2020504741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504741A5 JP2020504741A5 JP2019534245A JP2019534245A JP2020504741A5 JP 2020504741 A5 JP2020504741 A5 JP 2020504741A5 JP 2019534245 A JP2019534245 A JP 2019534245A JP 2019534245 A JP2019534245 A JP 2019534245A JP 2020504741 A5 JP2020504741 A5 JP 2020504741A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- group
- substituted
- ulm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(*)N(*)C(C(*)NC(C(C)N)=O)=O Chemical compound CC(*)N(*)C(C(*)NC(C(C)N)=O)=O 0.000 description 48
- DERXELLTUOVDQH-UHFFFAOYSA-N CN(C1)CC1F Chemical compound CN(C1)CC1F DERXELLTUOVDQH-UHFFFAOYSA-N 0.000 description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N C1Cc2ccccc2C1 Chemical compound C1Cc2ccccc2C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- IXHFNEAFAWRVCF-UHFFFAOYSA-N CC(C)C(NC)=O Chemical compound CC(C)C(NC)=O IXHFNEAFAWRVCF-UHFFFAOYSA-N 0.000 description 2
- ZAMXVCJJAQXCBT-UHFFFAOYSA-N CN(CC1)CC1F Chemical compound CN(CC1)CC1F ZAMXVCJJAQXCBT-UHFFFAOYSA-N 0.000 description 2
- YNZOOJLMTULUQT-XNWIYYODSA-N CN(CCC1)C1C(C1)N(C)C[C@@H]1F Chemical compound CN(CCC1)C1C(C1)N(C)C[C@@H]1F YNZOOJLMTULUQT-XNWIYYODSA-N 0.000 description 2
- VDOLWAQYIDIFME-WHFBIAKZSA-N CN(C[C@@H]1O)C[C@@H]1F Chemical compound CN(C[C@@H]1O)C[C@@H]1F VDOLWAQYIDIFME-WHFBIAKZSA-N 0.000 description 2
- SHAHSPDXKLHDNO-NKVNRFPTSA-N C[C@H](C[C@H]1F)C1C1N(C)CCCC1 Chemical compound C[C@H](C[C@H]1F)C1C1N(C)CCCC1 SHAHSPDXKLHDNO-NKVNRFPTSA-N 0.000 description 2
- KDSAXEOLUPBMBT-UHFFFAOYSA-N C=[Br]c1cc(c(C(c(c(F)ccc2NS(CC(CO)O)(=O)=O)c2F)=O)c[nH]2)c2nc1 Chemical compound C=[Br]c1cc(c(C(c(c(F)ccc2NS(CC(CO)O)(=O)=O)c2F)=O)c[nH]2)c2nc1 KDSAXEOLUPBMBT-UHFFFAOYSA-N 0.000 description 1
- RCOAYXFWTLIZRE-UHFFFAOYSA-N CC(C)(C)OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2Br)CC1)=O Chemical compound CC(C)(C)OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2Br)CC1)=O RCOAYXFWTLIZRE-UHFFFAOYSA-N 0.000 description 1
- ZTAZUQNGWKMQMQ-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1Oc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1)=O Chemical compound CC(C)(C)OC(N(C1)CC1Oc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1)=O ZTAZUQNGWKMQMQ-UHFFFAOYSA-N 0.000 description 1
- AGHUJPNOYUMQSV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1ccncc1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1ccncc1)=O AGHUJPNOYUMQSV-UHFFFAOYSA-N 0.000 description 1
- HFJDGWPENBIHKK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1cccc2c1C1OC1N(C(CCC(N1)=O)C1=O)C2=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1cccc2c1C1OC1N(C(CCC(N1)=O)C1=O)C2=O)=O HFJDGWPENBIHKK-UHFFFAOYSA-N 0.000 description 1
- KARHZPCIVJWKRD-MUUNZHRXSA-N CC(C)(C)OC(N1CCN(CCOCCOc(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NCCN(CC4)C[C@@H]4F)c3F)=O)c[nH]3)c3nc2)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(CCOCCOc(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NCCN(CC4)C[C@@H]4F)c3F)=O)c[nH]3)c3nc2)CC1)=O KARHZPCIVJWKRD-MUUNZHRXSA-N 0.000 description 1
- VTKNFMYABFTAQP-ZFGGDYGUSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(CNC(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(CNC(OC(C)(C)C)=O)=O VTKNFMYABFTAQP-ZFGGDYGUSA-N 0.000 description 1
- MGFBAMQBZTVJRS-UJSFRCSHSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCCN(CC1)CCN1C(CC1)=CC=C1c1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCCN(CC1)CCN1C(CC1)=CC=C1c1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1)=O MGFBAMQBZTVJRS-UJSFRCSHSA-N 0.000 description 1
- SRGDAQPTGJKAMK-RUDCESOPSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCOc(cc1)ccc1-[n](cc1-c(cc2CC3)ccc2C3=O)nc1-c1ccncc1)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCOc(cc1)ccc1-[n](cc1-c(cc2CC3)ccc2C3=O)nc1-c1ccncc1)=O SRGDAQPTGJKAMK-RUDCESOPSA-N 0.000 description 1
- NEJPPXZUWGFBDL-HTCXSVJXSA-N CC(C)C(C(N(C[C@@H](C1)O)[C@@H]1C(N[C@@H](C)c(cc1)ccc1-c1cnc[o]1)=O)=O)c1cc(C)n[o]1 Chemical compound CC(C)C(C(N(C[C@@H](C1)O)[C@@H]1C(N[C@@H](C)c(cc1)ccc1-c1cnc[o]1)=O)=O)c1cc(C)n[o]1 NEJPPXZUWGFBDL-HTCXSVJXSA-N 0.000 description 1
- SXFWBOTXORQGJN-UHFFFAOYSA-N CC(C)CCC(NC)=O Chemical compound CC(C)CCC(NC)=O SXFWBOTXORQGJN-UHFFFAOYSA-N 0.000 description 1
- IYDMGGPKSVWQRT-XZWHSSHBSA-N CC(C)Oc(cc(cc1)OC)c1C(N([C@@H]1c(cc2)ccc2Cl)C(N(CC2)CCN2C(C)=O)=O)=N[C@H]1c(cc1)ccc1Cl Chemical compound CC(C)Oc(cc(cc1)OC)c1C(N([C@@H]1c(cc2)ccc2Cl)C(N(CC2)CCN2C(C)=O)=O)=N[C@H]1c(cc1)ccc1Cl IYDMGGPKSVWQRT-XZWHSSHBSA-N 0.000 description 1
- CWWBCISTWBLCMI-CGYACHGYSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)N(Cc1ccccc11)C1=O Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)N(Cc1ccccc11)C1=O CWWBCISTWBLCMI-CGYACHGYSA-N 0.000 description 1
- FEWHVHJXHQNNTR-LFRRGIFHSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1C1=C(C/[O]=C(\c2ccccc2C2)/N2[C@@H](C(C)C)C(N(C[C@@H](C2)O)C2(C)C(NCc(cc2)ccc2C2=C(C/[O]=C(\c3c(C4)cccc3)/N4[C@@H](C(C)C)C(N(C[C@@H](C3)O)C3(C)C(NCc(cc3)ccc3C3=C(C)NCS3)=O)=O)NCS2)=O)=O)NCS1)=O)=O)N(Cc1ccccc11)C1=O Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1C1=C(C/[O]=C(\c2ccccc2C2)/N2[C@@H](C(C)C)C(N(C[C@@H](C2)O)C2(C)C(NCc(cc2)ccc2C2=C(C/[O]=C(\c3c(C4)cccc3)/N4[C@@H](C(C)C)C(N(C[C@@H](C3)O)C3(C)C(NCc(cc3)ccc3C3=C(C)NCS3)=O)=O)NCS2)=O)=O)NCS1)=O)=O)N(Cc1ccccc11)C1=O FEWHVHJXHQNNTR-LFRRGIFHSA-N 0.000 description 1
- VBGCXCMUKOYHJF-RZUBCFFCSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1cc(C)n[s]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1cc(C)n[s]1 VBGCXCMUKOYHJF-RZUBCFFCSA-N 0.000 description 1
- YQOGFIVOLUHWKC-BAGYTPMASA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1n[nH]c(C)c1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1n[nH]c(C)c1 YQOGFIVOLUHWKC-BAGYTPMASA-N 0.000 description 1
- GFRBMXSURJKHGR-HSALFYBXSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nc(C)n[s]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nc(C)n[s]1 GFRBMXSURJKHGR-HSALFYBXSA-N 0.000 description 1
- IHDWHNABLZYBIH-CZHRTVMISA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[n]1Cc1c(-c2ccc(CNC([C@H](C[C@H](C3)O)N3C([C@H](C(C)C)c3nc(C)n[o]3)=O)=O)cc2)[s]cn1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[n]1Cc1c(-c2ccc(CNC([C@H](C[C@H](C3)O)N3C([C@H](C(C)C)c3nc(C)n[o]3)=O)=O)cc2)[s]cn1 IHDWHNABLZYBIH-CZHRTVMISA-N 0.000 description 1
- NMQOREDOOXJWIK-HSALFYBXSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[o]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[o]1 NMQOREDOOXJWIK-HSALFYBXSA-N 0.000 description 1
- UAOHBORKFLZBPO-HSALFYBXSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[s]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[s]1 UAOHBORKFLZBPO-HSALFYBXSA-N 0.000 description 1
- YYSFFVIJGUQALQ-BAGYTPMASA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1C1=C(C)NCS1)=O)=O)c1n[o]c(C)c1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1C1=C(C)NCS1)=O)=O)c1n[o]c(C)c1 YYSFFVIJGUQALQ-BAGYTPMASA-N 0.000 description 1
- GJGXQAODWZABIH-DMTNHVFBSA-N CC(C)[C@@H](CN(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=N)N(C=C1C2=CC=CC1)C2=O Chemical compound CC(C)[C@@H](CN(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=N)N(C=C1C2=CC=CC1)C2=O GJGXQAODWZABIH-DMTNHVFBSA-N 0.000 description 1
- YKABBFAFVRCVPP-AULYBMBSSA-N CC(CN(CC1)CCC1O[C@H](C1)C[C@@H]1NC)=O Chemical compound CC(CN(CC1)CCC1O[C@H](C1)C[C@@H]1NC)=O YKABBFAFVRCVPP-AULYBMBSSA-N 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N CC1CCNCC1 Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- GCEWJCVKPTZCRU-UHFFFAOYSA-N CCC1OC1NC Chemical compound CCC1OC1NC GCEWJCVKPTZCRU-UHFFFAOYSA-N 0.000 description 1
- QKGZBDBAWVAAKZ-UHFFFAOYSA-N CCCC(CCC)CCC(NC)=O Chemical compound CCCC(CCC)CCC(NC)=O QKGZBDBAWVAAKZ-UHFFFAOYSA-N 0.000 description 1
- QNEGXSQWCRRYSN-QPJOQSLLSA-N CCCS(Nc(c(F)c1-[n](cc2/C(/C=N)=C/N)c(cc3)c2nc3N(C)C2CCNCC2)ccc1F)(=O)=O Chemical compound CCCS(Nc(c(F)c1-[n](cc2/C(/C=N)=C/N)c(cc3)c2nc3N(C)C2CCNCC2)ccc1F)(=O)=O QNEGXSQWCRRYSN-QPJOQSLLSA-N 0.000 description 1
- JNSRQBZQGWFBKE-UHFFFAOYSA-N CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C(CC4)CCN4c4cccc5c4COCN(C(CCC(N4)=O)C4=O)C5=O)nc3c(-c3cncnc3)c2)c1F)(=O)=O Chemical compound CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C(CC4)CCN4c4cccc5c4COCN(C(CCC(N4)=O)C4=O)C5=O)nc3c(-c3cncnc3)c2)c1F)(=O)=O JNSRQBZQGWFBKE-UHFFFAOYSA-N 0.000 description 1
- DWLFNIVXWUHBJQ-UHFFFAOYSA-N CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C4CCNCC4)nc3c(-c3cncnc3)c2)c1F)(=O)=O Chemical compound CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C4CCNCC4)nc3c(-c3cncnc3)c2)c1F)(=O)=O DWLFNIVXWUHBJQ-UHFFFAOYSA-N 0.000 description 1
- QXMBWAUFPOAKNN-OQKACKPTSA-N CCCS(Nc(ccc(F)c1C(c(c2c3)c[nH]c2ncc3N(CC2)CCN2C(CCCC(N[C@@H](C(C)(C)C)C(N(C[C@@H](C2)O)[C@@H]2C(NCc(cc2)ccc2-c2c(C)nc[s]2)=O)=O)=O)=O)=O)c1F)(=O)=O Chemical compound CCCS(Nc(ccc(F)c1C(c(c2c3)c[nH]c2ncc3N(CC2)CCN2C(CCCC(N[C@@H](C(C)(C)C)C(N(C[C@@H](C2)O)[C@@H]2C(NCc(cc2)ccc2-c2c(C)nc[s]2)=O)=O)=O)=O)=O)c1F)(=O)=O QXMBWAUFPOAKNN-OQKACKPTSA-N 0.000 description 1
- RTRZHLJEMYASNC-HJZXASKDSA-N CN(C(CCC1N(C(c(cc2)c3cc2N(CC2)CCN2c(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4/C5=N/O)nc2-c2ccncc2)=O)C3=O)=O)C1=O Chemical compound CN(C(CCC1N(C(c(cc2)c3cc2N(CC2)CCN2c(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4/C5=N/O)nc2-c2ccncc2)=O)C3=O)=O)C1=O RTRZHLJEMYASNC-HJZXASKDSA-N 0.000 description 1
- KDUOPPMIWCFSEU-UHFFFAOYSA-N CN(C(CCC1N(C(c(cc2)c3cc2NCCNc(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4C5=O)nc2-c2ccncc2)=O)C3=O)=O)C1=O Chemical compound CN(C(CCC1N(C(c(cc2)c3cc2NCCNc(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4C5=O)nc2-c2ccncc2)=O)C3=O)=O)C1=O KDUOPPMIWCFSEU-UHFFFAOYSA-N 0.000 description 1
- VDOLWAQYIDIFME-UHFFFAOYSA-N CN(CC1O)CC1F Chemical compound CN(CC1O)CC1F VDOLWAQYIDIFME-UHFFFAOYSA-N 0.000 description 1
- LCQASUWGXZDLLK-FXLOMAGBSA-N CN(CCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2/C3=N/O)nc1-c1ccncc1)c(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound CN(CCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2/C3=N/O)nc1-c1ccncc1)c(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O LCQASUWGXZDLLK-FXLOMAGBSA-N 0.000 description 1
- VDOLWAQYIDIFME-BRJRFNKRSA-N CN(C[C@H]1O)CC1F Chemical compound CN(C[C@H]1O)CC1F VDOLWAQYIDIFME-BRJRFNKRSA-N 0.000 description 1
- LARRZJQWINEIFU-UHFFFAOYSA-N CN1CC(CCN2CCNCC2)CC1 Chemical compound CN1CC(CCN2CCNCC2)CC1 LARRZJQWINEIFU-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- UPIHZCDTQBTGHI-UHFFFAOYSA-N CNCCOc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1 Chemical compound CNCCOc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1 UPIHZCDTQBTGHI-UHFFFAOYSA-N 0.000 description 1
- DYGHSFRVQSBDJP-RXMQYKEDSA-N CS(N(CC1)C[C@@H]1F)(=O)=O Chemical compound CS(N(CC1)C[C@@H]1F)(=O)=O DYGHSFRVQSBDJP-RXMQYKEDSA-N 0.000 description 1
- UATHGXSVZBAWEK-JFHPQLLQSA-N C[C@@H](C(N[C@@H](C)C(N(C1)[C@H](CN(CCc2ccccc2)C2)[C@H]2[C@@H]1OCCO[C@H](C1)C(CN(CCC2=CCCC=C2)C2)[C@@H]2N1C([C@H](COC(CCC(OC)=O)=O)NC([C@H](N)NC)=O)=O)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C)C(N(C1)[C@H](CN(CCc2ccccc2)C2)[C@H]2[C@@H]1OCCO[C@H](C1)C(CN(CCC2=CCCC=C2)C2)[C@@H]2N1C([C@H](COC(CCC(OC)=O)=O)NC([C@H](N)NC)=O)=O)=O)=O)NC UATHGXSVZBAWEK-JFHPQLLQSA-N 0.000 description 1
- IBBHIZXRMBKKII-IYNDAXALSA-N C[C@@H](C(N[C@@H](C1CCCCC1)C(N(CC[C@@H]1C)[C@@H]1C(Nc1cc(C)n[n]1-c1ccccc1)=O)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C1CCCCC1)C(N(CC[C@@H]1C)[C@@H]1C(Nc1cc(C)n[n]1-c1ccccc1)=O)=O)=O)NC IBBHIZXRMBKKII-IYNDAXALSA-N 0.000 description 1
- AADMRSQDLRYQQU-UHFFFAOYSA-N Cc1cc(CCCCCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCCCCCN2CCN(C)CC2)n[o]1 AADMRSQDLRYQQU-UHFFFAOYSA-N 0.000 description 1
- NKJLAVFMTFUYGP-UHFFFAOYSA-N Cc1cc(CCCCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCCCCN2CCN(C)CC2)n[o]1 NKJLAVFMTFUYGP-UHFFFAOYSA-N 0.000 description 1
- PXRKWVGPKRKKFP-UHFFFAOYSA-N Cc1cc(CCCOCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCCOCCN2CCN(C)CC2)n[o]1 PXRKWVGPKRKKFP-UHFFFAOYSA-N 0.000 description 1
- CCGOLKRCFVKMCO-UHFFFAOYSA-N Cc1cc(CCOCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCOCCN2CCN(C)CC2)n[o]1 CCGOLKRCFVKMCO-UHFFFAOYSA-N 0.000 description 1
- BOECVYQYFLWQNP-UHFFFAOYSA-N Cc1cc(COCCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(COCCCN2CCN(C)CC2)n[o]1 BOECVYQYFLWQNP-UHFFFAOYSA-N 0.000 description 1
- OFOLFJNDUSEUPT-UHFFFAOYSA-N Cc1cc(COCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(COCCN2CCN(C)CC2)n[o]1 OFOLFJNDUSEUPT-UHFFFAOYSA-N 0.000 description 1
- LTCXOHTXCPOVIV-UMSPYCQHSA-N Cc1cc(O[C@H](C2)C[C@@H]2NC)ccc1 Chemical compound Cc1cc(O[C@H](C2)C[C@@H]2NC)ccc1 LTCXOHTXCPOVIV-UMSPYCQHSA-N 0.000 description 1
- QEBVSEQGCUZGCV-SECBINFHSA-N Nc1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 Chemical compound Nc1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 QEBVSEQGCUZGCV-SECBINFHSA-N 0.000 description 1
- UQPSXJLSPRHBBA-OQWWRJADSA-N O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCCOc3cccc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 Chemical compound O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCCOc3cccc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 UQPSXJLSPRHBBA-OQWWRJADSA-N 0.000 description 1
- CFJMFGGNHCSIHD-VRPJDWIJSA-N O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCOCCOc(cc3)cc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 Chemical compound O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCOCCOc(cc3)cc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 CFJMFGGNHCSIHD-VRPJDWIJSA-N 0.000 description 1
- RQPANKYMENZMFC-PHVLXYFRSA-N O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCCCOc2cc(-c(cccc3C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)ccc2)nc1-c1ccncc1 Chemical compound O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCCCOc2cc(-c(cccc3C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)ccc2)nc1-c1ccncc1 RQPANKYMENZMFC-PHVLXYFRSA-N 0.000 description 1
- KGZUGSKPAMJRRC-UHFFFAOYSA-N O=C(CC1)c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCc(cccc2)c2OCCOCCCOc(cccc2C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)nc1-c1ccncc1 Chemical compound O=C(CC1)c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCc(cccc2)c2OCCOCCCOc(cccc2C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)nc1-c1ccncc1 KGZUGSKPAMJRRC-UHFFFAOYSA-N 0.000 description 1
- DXQDVHBZWPXJPA-UHFFFAOYSA-N O=C(c(cc1)c2cc1N(C1)CC1N(C1)CC1Oc(cc1)ccc1-[n]1nc(C3C=CN=CC3)c(Br)c1)N(C(CCC(N1)=O)C1=O)C2=O Chemical compound O=C(c(cc1)c2cc1N(C1)CC1N(C1)CC1Oc(cc1)ccc1-[n]1nc(C3C=CN=CC3)c(Br)c1)N(C(CCC(N1)=O)C1=O)C2=O DXQDVHBZWPXJPA-UHFFFAOYSA-N 0.000 description 1
- CCERGJGFOODHOI-NDEPHWFRSA-N O=C(c1c2c(OCCCCN(CC3)CCN3c(cc3)ccc3-[n](cc3Br)nc3-c3ccncc3)ccc1)N([C@@H](CCC(N1)=O)C1=O)C2=O Chemical compound O=C(c1c2c(OCCCCN(CC3)CCN3c(cc3)ccc3-[n](cc3Br)nc3-c3ccncc3)ccc1)N([C@@H](CCC(N1)=O)C1=O)C2=O CCERGJGFOODHOI-NDEPHWFRSA-N 0.000 description 1
- UTSZNJIEZABRKU-OAQYLSRUSA-N O=CCN(CC1)CCN1c(cc1)ccc1-c1cc(c(C(c(c(F)c(cc2)NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 Chemical compound O=CCN(CC1)CCN1c(cc1)ccc1-c1cc(c(C(c(c(F)c(cc2)NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 UTSZNJIEZABRKU-OAQYLSRUSA-N 0.000 description 1
- RFWLATFOOGPHAS-AREMUKBSSA-N OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NS(N(CC4)C[C@@H]4F)(=O)=O)c3F)=O)c[nH]3)c3nc2)CC1)=O Chemical compound OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NS(N(CC4)C[C@@H]4F)(=O)=O)c3F)=O)c[nH]3)c3nc2)CC1)=O RFWLATFOOGPHAS-AREMUKBSSA-N 0.000 description 1
- SJCTVMPUXINNPA-UHFFFAOYSA-N OC(c(cc1)c2cc1N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc3)cc(CC4)c3C4=O)nc1-c1ccncc1)N(C(CCC(N1)=O)C1=O)C2=O Chemical compound OC(c(cc1)c2cc1N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc3)cc(CC4)c3C4=O)nc1-c1ccncc1)N(C(CCC(N1)=O)C1=O)C2=O SJCTVMPUXINNPA-UHFFFAOYSA-N 0.000 description 1
- YEFDWSQVRHOJFI-UHFFFAOYSA-N OCCCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1csncc1 Chemical compound OCCCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1csncc1 YEFDWSQVRHOJFI-UHFFFAOYSA-N 0.000 description 1
- PKXOFPCXFBCGEA-MECOZAJYSA-N OCCOc1cccc2c1C1OC1N([C@@H](CCC(N1)=O)C1=O)C2=O Chemical compound OCCOc1cccc2c1C1OC1N([C@@H](CCC(N1)=O)C1=O)C2=O PKXOFPCXFBCGEA-MECOZAJYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
Images
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023015526A JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2024180795A JP2025016525A (ja) | 2016-12-23 | 2024-10-16 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438803P | 2016-12-23 | 2016-12-23 | |
| US62/438,803 | 2016-12-23 | ||
| US201762582698P | 2017-11-07 | 2017-11-07 | |
| US62/582,698 | 2017-11-07 | ||
| PCT/US2017/068322 WO2018119448A1 (en) | 2016-12-23 | 2017-12-22 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015526A Division JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504741A JP2020504741A (ja) | 2020-02-13 |
| JP2020504741A5 true JP2020504741A5 (enExample) | 2021-02-04 |
| JP7679173B2 JP7679173B2 (ja) | 2025-05-19 |
Family
ID=62625473
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534245A Active JP7679173B2 (ja) | 2016-12-23 | 2017-12-22 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2023015526A Pending JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2024180795A Pending JP2025016525A (ja) | 2016-12-23 | 2024-10-16 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015526A Pending JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2024180795A Pending JP2025016525A (ja) | 2016-12-23 | 2024-10-16 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10723717B2 (enExample) |
| EP (1) | EP3558994A4 (enExample) |
| JP (3) | JP7679173B2 (enExample) |
| KR (3) | KR102839545B1 (enExample) |
| CN (2) | CN110741004B (enExample) |
| AU (2) | AU2017382436C1 (enExample) |
| BR (1) | BR112019012878A2 (enExample) |
| CA (1) | CA3047784A1 (enExample) |
| CO (1) | CO2019007894A2 (enExample) |
| IL (3) | IL294423B2 (enExample) |
| MX (2) | MX2019007649A (enExample) |
| WO (1) | WO2018119448A1 (enExample) |
Families Citing this family (145)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2894994C (en) | 2012-12-21 | 2019-11-12 | National Institute Of Radiological Sciences | Compounds for imaging tau proteins that accumulate in brain |
| AU2014364589B2 (en) | 2013-12-18 | 2020-02-27 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US11352351B2 (en) | 2015-01-20 | 2022-06-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2018053354A1 (en) | 2016-09-15 | 2018-03-22 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| KR20230127371A (ko) | 2016-11-01 | 2023-08-31 | 아비나스 오퍼레이션스, 인코포레이티드 | 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법 |
| IL297717A (en) | 2016-12-01 | 2022-12-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| MX2019007649A (es) | 2016-12-23 | 2019-09-10 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente. |
| WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| WO2018119441A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| EP3577109A4 (en) | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM |
| CN110545853A (zh) * | 2017-04-28 | 2019-12-06 | 石英治疗有限公司 | Raf降解偶联化合物 |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
| EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| US11110177B2 (en) | 2017-11-10 | 2021-09-07 | The Regents Of The University Of Michigan | ASH1L degraders and methods of treatment therewith |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| EP3743066A4 (en) | 2018-01-26 | 2021-09-08 | Yale University | IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE |
| KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
| JP7720698B2 (ja) | 2018-04-04 | 2025-08-08 | アルビナス・オペレーションズ・インコーポレイテッド | タンパク質分解の調節因子および関連する使用方法 |
| JP7367908B2 (ja) * | 2018-04-09 | 2023-10-24 | 上海科技大学 | 標的タンパク質分解化合物、その抗腫瘍応用、その中間体および中間体の応用 |
| EP3774772A1 (en) * | 2018-04-13 | 2021-02-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| JP7293343B2 (ja) | 2018-05-09 | 2023-06-19 | アプリノイア セラピューティクス リミテッド | ヘテロアリール化合物及びその使用 |
| US20190375732A1 (en) | 2018-05-14 | 2019-12-12 | David Hung | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| CA3103385A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| EP3831811A4 (en) | 2018-07-31 | 2022-04-20 | Fimecs, Inc. | HETEROCYCLIC COMPOUND |
| CN112912376A (zh) | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
| CA3110267A1 (en) | 2018-08-22 | 2020-02-27 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| MX2021002559A (es) * | 2018-09-07 | 2021-07-21 | Arvinas Operations Inc | Compuestos policiclicos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma rapidamente acelerado. |
| CN110963994B (zh) * | 2018-09-30 | 2022-02-08 | 中国科学院上海药物研究所 | 异吲哚啉类化合物、其制备方法、药物组合物及用途 |
| US11691984B2 (en) | 2018-10-12 | 2023-07-04 | The Scripps Research Institute | Compounds and methods for DCAF-mediated protein degradation |
| EP3891128A4 (en) * | 2018-12-05 | 2022-08-17 | Vividion Therapeutics, Inc. | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEOSUBSTRATE RECRUITMENT |
| EP3896062A4 (en) * | 2018-12-06 | 2022-06-15 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | ISOINDOLINE COMPOUND, METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE OF ISOINDOLINE COMPOUND |
| CN120698985A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2020162725A1 (ko) * | 2019-02-07 | 2020-08-13 | 한국화학연구원 | 표적 단백질 ｅｅｄ 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 ｅｅｄ, ｅｚｈ2, 또는 ｐｒｃ2 관련 질환의 예방 또는 치료용 약학적 조성물 |
| US11389438B2 (en) * | 2019-02-25 | 2022-07-19 | Chdi Foundation, Inc. | Compounds for targeting mutant huntingtin protein and uses thereof |
| US12186401B2 (en) | 2019-03-01 | 2025-01-07 | Ontario Institute for Cancer Research (OICR) and Sinai Health System | Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated uses |
| KR20210152515A (ko) | 2019-04-12 | 2021-12-15 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| WO2020214555A1 (en) | 2019-04-16 | 2020-10-22 | Northwestern University | Bifunctional compounds comprising apcin-a and their use in the treatment of cancer |
| KR20220008869A (ko) | 2019-05-14 | 2022-01-21 | 누베이션 바이오 인크. | 항암 핵 호르몬 수용체-표적화 화합물 |
| AU2020281410A1 (en) * | 2019-05-31 | 2021-10-07 | Haisco Pharmaceuticals Pte. Ltd. | BTK inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
| WO2021016521A1 (en) * | 2019-07-25 | 2021-01-28 | Beth Israel Deaconess Medical Center, Inc. | Photo induced control of protein destruction |
| JP7764027B2 (ja) | 2019-07-31 | 2025-11-05 | ファイメクス株式会社 | 複素環化合物 |
| JP2021024787A (ja) | 2019-07-31 | 2021-02-22 | ファイメクス株式会社 | 複素環化合物 |
| EP4021450B1 (en) | 2019-08-26 | 2025-11-05 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| EP4089083A1 (en) * | 2019-09-23 | 2022-11-16 | Accutar Biotechnology Inc. | Piperidine-2,6-dione substituted isoindoles in the preparation of substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof |
| US11535606B2 (en) | 2019-09-23 | 2022-12-27 | Accutar Biotechnology Inc. | Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof |
| CN114761003B (zh) * | 2019-09-23 | 2023-12-29 | 冰洲石生物科技公司 | 具有雄激素受体降解活性的新型脲类及其用途 |
| AU2020368542B2 (en) | 2019-10-17 | 2024-02-29 | Arvinas Operations, Inc. | Bifunctional molecules containing an E3 ubiquitine ligase binding moiety linked to a BCL6 targeting moiety |
| KR20220100921A (ko) | 2019-11-13 | 2022-07-18 | 아프리노이아 테라퓨틱스 리미티드 | 타우 단백질 응집체를 분해하기 위한 화합물 및 이의 용도 |
| TW202131930A (zh) | 2019-11-13 | 2021-09-01 | 美商諾維雪碧歐公司 | 抗癌核荷爾蒙受體標靶化合物 |
| IL293027A (en) | 2019-11-19 | 2022-07-01 | Bristol Myers Squibb Co | Compounds useful as inhibitors of Helios protein |
| CN110950877B (zh) * | 2019-12-11 | 2022-06-28 | 齐鲁工业大学 | 一种双检测荧光探针、制备方法及其在检测硫化氢和铜离子中的应用 |
| EP4076464A4 (en) * | 2019-12-17 | 2024-06-12 | Orionis Biosciences, Inc. | COMPOUNDS FOR MODULATION OF PROTEIN RECRUITMENT AND/OR DEGRADATION |
| US20230099031A1 (en) * | 2019-12-17 | 2023-03-30 | Orionis Biosciences, Inc. | Bifunctional agents for protein recruitment and/or degradation |
| IL293530A (en) | 2019-12-18 | 2022-08-01 | Novartis Ag | Derivatives of 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione and their uses |
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| MX2022007659A (es) | 2019-12-20 | 2022-07-19 | C4 Therapeutics Inc | Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr). |
| BR112022014623A2 (pt) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| CN115697989B (zh) | 2020-02-26 | 2025-03-18 | 上海睿跃生物科技有限公司 | 原肌球蛋白受体激酶(trk)降解化合物和使用方法 |
| AU2021231898A1 (en) | 2020-03-05 | 2022-10-27 | C4 Therapeutics, Inc. | Compounds for targeted degradation of BRD9 |
| WO2021207172A1 (en) * | 2020-04-06 | 2021-10-14 | Arvinas Operations, Inc. | Compounds and methods for targeted degradation of kras |
| BR112022025061A2 (pt) | 2020-06-09 | 2023-01-31 | Prelude Therapeutics Inc | Compostos que estabelecem como alvo brm e métodos de uso associados |
| CA3181979A1 (en) * | 2020-06-17 | 2021-12-23 | Fleur M. FERGUSON | Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an e3-ligase system |
| WO2021255212A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Braf degraders |
| WO2021255213A1 (en) * | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Heterobifunctional compounds as degraders of braf |
| KR102559329B1 (ko) * | 2020-07-02 | 2023-07-25 | 포항공과대학교 산학협력단 | 신규한 프로탁 키메라 화합물, 이를 포함하는 표적 단백질 분해를 통한 질환의 예방, 개선 또는 치료용 약학적 조성물 |
| CA3186548A1 (en) | 2020-07-21 | 2022-01-27 | Song Hee Lee | Compound for androgen receptor degradation, and pharmaceutical use thereof |
| JP2023538517A (ja) | 2020-08-05 | 2023-09-08 | シーフォー セラピューティクス， インコーポレイテッド | Ｒｅｔの標的分解のための化合物 |
| EP4192825A4 (en) * | 2020-08-07 | 2024-08-28 | Cornell University | CURE PRO MOLECULES THERAPEUTICALLY USEFUL FOR E3 LIGASE-MEDIATED PROTEIN DEGRADATION, AND METHODS OF PREPARATION AND USE THEREOF |
| US20230277553A1 (en) * | 2020-08-07 | 2023-09-07 | Cornell University | Therapeutic composition of cure-pro compounds for targeted degradation of bet domain proteins, and methods of making and usage |
| CN117062814A (zh) * | 2020-08-28 | 2023-11-14 | 阿维纳斯运营公司 | 快速加速纤维肉瘤蛋白降解的化合物和相关使用方法 |
| EP4204418A1 (en) * | 2020-08-28 | 2023-07-05 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| EP4211128A1 (en) | 2020-09-14 | 2023-07-19 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| EP4217352A4 (en) | 2020-09-23 | 2024-04-10 | St. Jude Children's Research Hospital, Inc. | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
| WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| KR102532692B1 (ko) * | 2021-03-15 | 2023-05-16 | (주)피알지에스앤텍 | 신경섬유종증 2형 증후군 예방 또는 치료용 조성물 |
| BR112023019420A2 (pt) | 2021-03-23 | 2023-10-24 | Nuvation Bio Inc | Compostos de direcionamento ao receptor de hormônio nuclear anticâncer |
| RS66982B1 (sr) | 2021-04-06 | 2025-07-31 | Bristol Myers Squibb Co | Piridinil supstituisana oksoizoindolinska jedinjenja |
| EP4323352A1 (en) | 2021-04-16 | 2024-02-21 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| EP4334314A1 (en) | 2021-05-03 | 2024-03-13 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CA3217417A1 (en) | 2021-05-05 | 2022-11-10 | Kevin M. Guckian | Compounds for targeting degradation of bruton's tyrosine kinase |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| AR126052A1 (es) | 2021-06-03 | 2023-09-06 | Novartis Ag | Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos |
| AU2022288713A1 (en) | 2021-06-07 | 2023-12-21 | Dana-Farber Cancer Institute, Inc. | Inhibitors of ttbk1 |
| MX2023014059A (es) | 2021-06-08 | 2024-03-12 | C4 Therapeutics Inc | Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante. |
| AU2022289610A1 (en) | 2021-06-09 | 2024-01-25 | The Scripps Research Institute | Long-acting dual gip/glp-1 peptide conjugates and methods of use |
| AU2022308734A1 (en) | 2021-07-07 | 2024-02-22 | Biogen Ma Inc. | Compounds for targeting degradation of irak4 proteins |
| US20250018046A1 (en) | 2021-07-07 | 2025-01-16 | Biogen Ma Inc | Compounds for targeting degradation of irak4 proteins |
| WO2023023941A1 (en) * | 2021-08-24 | 2023-03-02 | Biofront Ltd (Cayman) | Hpk1 degraders, compositions comprising the hpki degrader, and methods of using the same |
| WO2023034411A1 (en) | 2021-09-01 | 2023-03-09 | Oerth Bio Llc | Compositions and methods for targeted degradation of proteins in a plant cell |
| EP4421071A1 (en) * | 2021-10-22 | 2024-08-28 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| CN115894450B (zh) * | 2021-11-30 | 2023-09-12 | 山东如至生物医药科技有限公司 | 一种新型多环类化合物及其组合物和用途 |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023143494A1 (zh) * | 2022-01-28 | 2023-08-03 | 甘李药业股份有限公司 | 新型protac化合物 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| IL316803A (en) | 2022-06-06 | 2025-01-01 | C4 Therapeutics Inc | Bicyclic glutarimide-modified cervalon-binding agents |
| CA3260083A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences Inc | CD73 COMPOUNDS |
| WO2024050016A1 (en) | 2022-08-31 | 2024-03-07 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| TW202432544A (zh) | 2022-09-07 | 2024-08-16 | 美商亞文納營運公司 | 快速加速纖維肉瘤降解化合物及相關使用方法 |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024140638A1 (zh) * | 2022-12-27 | 2024-07-04 | 标新生物医药科技(上海)有限公司 | 基于硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用 |
| TW202444727A (zh) | 2023-01-26 | 2024-11-16 | 美商艾維納斯手術有限公司 | 基於cereblon之kras降解protac及其相關用途 |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025007000A1 (en) | 2023-06-30 | 2025-01-02 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096855A1 (en) | 2023-11-02 | 2025-05-08 | Kumquat Biosciences Inc. | Degraders and uses thereof |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137500A1 (en) | 2023-12-21 | 2025-06-26 | Dana-Farber Cancer Institute, Inc. | Kinase inhibition and degradation |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025235298A1 (en) * | 2024-05-07 | 2025-11-13 | Nikang Therapeutics, Inc. | Bifunctional compounds containing thiazolyl derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL195916B1 (pl) | 1996-07-24 | 2007-11-30 | Celgene Corp | Izomery optyczne podstawionej 1-okso-izoindoliny i 1,3-diokso-izoindoliny, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie |
| JP4903922B2 (ja) | 1997-05-14 | 2012-03-28 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 選択された蛋白質を分解する複合化合物 |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| AU769652B2 (en) | 1999-05-05 | 2004-01-29 | Cubist Pharmaceuticals, Inc. | Novel prolines as antimicrobial agents |
| WO2002020740A2 (en) | 2000-09-08 | 2002-03-14 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| JP2005507363A (ja) | 2001-02-16 | 2005-03-17 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 血管新生阻害トリペプチド、組成物およびそれらの使用方法 |
| HN2002000136A (es) | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
| US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| US20060128632A1 (en) | 2002-07-02 | 2006-06-15 | Sharma Sushil K | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| WO2005007621A2 (en) | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| EP1718300A4 (en) | 2004-01-16 | 2008-05-14 | Univ Michigan | CONFORMATIVELY IMPROVED SMAC MIMETIKA AND ITS USES |
| AU2005228950B2 (en) | 2004-03-23 | 2012-02-02 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
| WO2005097791A1 (en) | 2004-04-07 | 2005-10-20 | Novartis Ag | Inhibitors of iap |
| WO2006014361A1 (en) | 2004-07-02 | 2006-02-09 | Genentech, Inc. | Inhibitors of iap |
| EA019420B1 (ru) | 2004-12-20 | 2014-03-31 | Дженентех, Инк. | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| DK1851200T3 (da) | 2005-02-25 | 2014-04-14 | Tetralogic Pharm Corp | Dimere iap-inhibitorer |
| CN100383139C (zh) | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物 |
| WO2006113942A2 (en) | 2005-04-20 | 2006-10-26 | Schering Corporation | Method of inhibiting cathepsin activity |
| WO2007002433A1 (en) * | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors |
| BRPI0614995A2 (pt) | 2005-08-31 | 2010-01-12 | Celgene Corp | composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade terapêutica ou profilaticamente eficaz de um composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, e, forma de dosagem unitária única |
| CA2643267A1 (en) | 2006-03-03 | 2007-09-20 | Novartis Ag | N-formyl hydroxylamine compounds |
| WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| AU2007248473B2 (en) | 2006-05-05 | 2011-01-27 | The Regents Of The University Of Michigan | Bivalent Smac mimetics and the uses thereof |
| AU2007275415A1 (en) | 2006-07-20 | 2008-01-24 | Ligand Pharmaceuticals Incorporated | Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation |
| US20100056495A1 (en) | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| RU2448101C2 (ru) | 2006-08-30 | 2012-04-20 | Селджин Корпорейшн | 5-замещенные изоиндолиновые соединения |
| CL2007002513A1 (es) | 2006-08-30 | 2008-04-04 | Celgene Corp Soc Organizada Ba | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. |
| EP2089391B1 (en) | 2006-11-03 | 2013-01-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| WO2008109057A1 (en) | 2007-03-02 | 2008-09-12 | Dana-Farber Cancer Institute, Inc. | Organic compounds and their uses |
| EP2079309B1 (en) | 2007-04-12 | 2015-11-11 | Joyant Pharmaceuticals Inc | SMAC MIMEE DIMERS AND TRIMERS USEFUL AS ANTICANCER AGENTS |
| BRPI0810522B8 (pt) | 2007-04-13 | 2021-05-25 | Univ Michigan Regents | compostos miméticos diazo bicíclicos de smac, composição farmacêutica e kit compreendendo ditos compostos e uso dos mesmos para o tratamento de câncer |
| AR066348A1 (es) | 2007-04-30 | 2009-08-12 | Genentech Inc | Inhibidores de las iap |
| WO2008144925A1 (en) | 2007-05-30 | 2008-12-04 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| KR20100038108A (ko) | 2007-07-25 | 2010-04-12 | 브리스톨-마이어스 스큅 컴퍼니 | 트리아진 키나제 억제제 |
| EP2058312A1 (en) | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
| PE20140963A1 (es) | 2008-10-29 | 2014-08-06 | Celgene Corp | Compuestos de isoindolina para el tratamiento de cancer |
| US20120135089A1 (en) | 2009-03-17 | 2012-05-31 | Stockwell Brent R | E3 ligase inhibitors |
| US8614201B2 (en) | 2009-06-05 | 2013-12-24 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of TRPA1 |
| WO2011008260A2 (en) | 2009-07-13 | 2011-01-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| US8551955B2 (en) | 2009-10-28 | 2013-10-08 | Joyant Pharmaceuticals, Inc. | Dimeric Smac mimetics |
| SG10201501062SA (en) | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| AU2011272860A1 (en) | 2010-06-30 | 2013-02-07 | Brandeis University | Small-molecule-targeted protein degradation |
| CN103261169A (zh) | 2010-09-24 | 2013-08-21 | 密歇根大学董事会 | 脱泛素酶抑制剂及其应用方法 |
| EP2649099A4 (en) | 2010-12-07 | 2016-10-19 | Univ Yale | SMALL MOLECULAR HYDROPHOBIC LABELING OF FUSION PROTEINS AND INDUCED REMOVAL FROM THIS |
| US20140243282A1 (en) | 2010-12-31 | 2014-08-28 | Satish Reddy Kallam | Methods and compositions for designing novel conjugate therapeutics |
| US8889684B2 (en) * | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| AU2012214762B2 (en) * | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN103688176A (zh) | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
| JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 |
| WO2013071039A1 (en) | 2011-11-09 | 2013-05-16 | Ensemble Therapeutics | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| JP2015504425A (ja) | 2011-11-09 | 2015-02-12 | アンサンブル・セラピューティクス | アポトーシスのインヒビターを阻害するための大環状化合物 |
| CN103159736B (zh) * | 2011-12-10 | 2015-05-13 | 通化济达医药有限公司 | 取代的吡唑激酶抑制剂 |
| EP2797888B1 (en) * | 2011-12-31 | 2016-06-08 | BeiGene, Ltd. | Fused tricyclic compounds as raf kinase inhibitors |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| US20150141470A1 (en) * | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| EP2846784A4 (en) | 2012-05-11 | 2016-03-09 | Univ Yale | COMPOUNDS FOR PROMOTING PROTEIN REMOVAL AND PROCESS THEREFOR |
| WO2013175417A1 (en) | 2012-05-24 | 2013-11-28 | Novartis Ag | Pyrrolopyrrolidinone compounds |
| SG11201406889WA (en) | 2012-05-30 | 2015-02-27 | Hoffmann La Roche | Substituted pyrrolidine-2-carboxamides |
| US9345740B2 (en) | 2012-07-10 | 2016-05-24 | Bristol-Myers Squibb Company | IAP antagonists |
| SI2880447T1 (sl) | 2012-07-31 | 2019-09-30 | Novartis Ag | Označevalci povezani z občutljivostjo na inhibitorje humanega dvominutnega 2 proteina (mdm2) |
| US9453048B2 (en) | 2012-08-09 | 2016-09-27 | Bristol-Myers Squibb Company | IAP antagonists |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| EP2897949B1 (en) | 2012-09-18 | 2018-01-10 | Bristol-Myers Squibb Company | Iap antagonists |
| TWI569799B (zh) | 2012-09-21 | 2017-02-11 | 安羅格製藥股份有限公司 | 抑制組成型活性磷酸化ｆｌｔ３激酶的方法 |
| EP2903998B1 (en) | 2012-10-02 | 2017-03-15 | Bristol-Myers Squibb Company | Iap antagonists |
| EP2917218B1 (en) | 2012-11-09 | 2017-01-04 | Ensemble Therapeutics Corporation | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| AR094116A1 (es) | 2012-12-20 | 2015-07-08 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de hdm2 |
| EP2934535B1 (en) | 2012-12-20 | 2017-07-19 | Merck Sharp & Dohme Corp. | Substituted pyrrolopyrimidines as hdm2 inhibitors |
| EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
| GB201311910D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel Compounds |
| NL2011274C2 (en) | 2013-08-06 | 2015-02-09 | Illumicare Ip B V 51 | Groundbreaking platform technology for specific binding to necrotic cells. |
| AU2014223547B2 (en) | 2013-02-28 | 2017-11-16 | Amgen Inc. | A benzoic acid derivative MDM2 inhibitor for the treatment of cancer |
| JP6377123B2 (ja) | 2013-03-14 | 2018-08-22 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物 |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| EP3019517A1 (en) | 2013-07-12 | 2016-05-18 | Bristol-Myers Squibb Company | Iap antagonists |
| US20150259288A1 (en) | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| KR20250127179A (ko) | 2014-04-14 | 2025-08-26 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| US20160022642A1 (en) | 2014-07-25 | 2016-01-28 | Yale University | Compounds Useful for Promoting Protein Degradation and Methods Using Same |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US11352351B2 (en) | 2015-01-20 | 2022-06-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| GB201504314D0 (en) * | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
| HK1249058A1 (zh) | 2015-03-18 | 2018-10-26 | Arvinas, Inc. | 用於增强靶向蛋白质降解的化合物和方法 |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016197032A1 (en) * | 2015-06-04 | 2016-12-08 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CA2988430A1 (en) | 2015-07-10 | 2017-01-19 | Arvinas, Inc. | Mdm2-based modulators of proteolysis and associated methods of use |
| RU2018105094A (ru) | 2015-07-13 | 2019-08-14 | Арвинас, Инк. | Модуляторы протеолиза на основе аланина и связанные с ними способы применения |
| EP3331905B1 (en) | 2015-08-06 | 2022-10-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN108366992A (zh) | 2015-11-02 | 2018-08-03 | 耶鲁大学 | 蛋白水解靶向嵌合体化合物及其制备和应用方法 |
| CA3017740A1 (en) | 2016-03-16 | 2017-09-21 | Pearlie BURNETTE | Small molecules against cereblon to enhance effector t cell function |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| JP6968823B2 (ja) | 2016-04-22 | 2021-11-17 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｅｇｆｒの分解のための二官能性分子、及び使用方法 |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| WO2018053354A1 (en) | 2016-09-15 | 2018-03-22 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| HUE070289T2 (hu) | 2016-10-11 | 2025-05-28 | Arvinas Operations Inc | Vegyületek és módszerek az androgénreceptor célzott lebontására |
| KR20230127371A (ko) | 2016-11-01 | 2023-08-31 | 아비나스 오퍼레이션스, 인코포레이티드 | 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법 |
| EP3544957B1 (en) * | 2016-11-22 | 2024-05-29 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| IL297717A (en) | 2016-12-01 | 2022-12-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| MX2019007649A (es) | 2016-12-23 | 2019-09-10 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente. |
| WO2018119441A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
| WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| EP3577109A4 (en) | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM |
| JP7227912B2 (ja) | 2017-02-08 | 2023-02-24 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | キメラ抗原受容体の調節 |
| CN110545853A (zh) | 2017-04-28 | 2019-12-06 | 石英治疗有限公司 | Raf降解偶联化合物 |
-
2017
- 2017-12-22 MX MX2019007649A patent/MX2019007649A/es unknown
- 2017-12-22 KR KR1020237026280A patent/KR102839545B1/ko active Active
- 2017-12-22 KR KR1020257024694A patent/KR20250117470A/ko active Pending
- 2017-12-22 EP EP17882647.5A patent/EP3558994A4/en active Pending
- 2017-12-22 CN CN201780087131.XA patent/CN110741004B/zh active Active
- 2017-12-22 WO PCT/US2017/068322 patent/WO2018119448A1/en not_active Ceased
- 2017-12-22 CN CN202311248251.7A patent/CN117510491A/zh active Pending
- 2017-12-22 IL IL294423A patent/IL294423B2/en unknown
- 2017-12-22 CA CA3047784A patent/CA3047784A1/en active Pending
- 2017-12-22 JP JP2019534245A patent/JP7679173B2/ja active Active
- 2017-12-22 AU AU2017382436A patent/AU2017382436C1/en active Active
- 2017-12-22 KR KR1020197021537A patent/KR102564201B1/ko active Active
- 2017-12-22 US US15/853,166 patent/US10723717B2/en active Active
- 2017-12-22 BR BR112019012878A patent/BR112019012878A2/pt unknown
-
2019
- 2019-06-17 IL IL267410A patent/IL267410A/en unknown
- 2019-06-21 MX MX2023009031A patent/MX2023009031A/es unknown
- 2019-07-23 CO CONC2019/0007894A patent/CO2019007894A2/es unknown
-
2021
- 2021-01-08 AU AU2021200099A patent/AU2021200099B2/en active Active
-
2023
- 2023-02-03 JP JP2023015526A patent/JP2023065395A/ja active Pending
- 2023-07-24 IL IL304704A patent/IL304704A/en unknown
-
2024
- 2024-10-16 JP JP2024180795A patent/JP2025016525A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7679173B2 (ja) | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 | |
| JP2020504741A5 (enExample) | ||
| KR102642203B1 (ko) | 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법 | |
| JP7266526B6 (ja) | エストロゲン受容体タンパク質分解性の調節因子およびその関連方法 | |
| US11986531B2 (en) | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | |
| CN119019369A (zh) | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 | |
| JP2020505327A (ja) | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 | |
| JP2020505327A5 (enExample) | ||
| IL302595A (en) | Servalon ligands and bifunctional compounds containing them | |
| JP2020506914A5 (enExample) | ||
| RU2830173C2 (ru) | Полициклические соединения и способы целенаправленной деградации полипептидов быстро ускоренной фибросаркомы | |
| RU2782458C2 (ru) | Соединения и способы нацеленного расщепления полипептидов быстропрогрессирующей фибросаркомы |